The White House has officially refuted claims suggesting that President Donald Trump received prioritized access to an experimental weight-loss medication. The controversy stems from a STAT News investigation, which revealed that an unidentified 79-year-old patient secured access to Eli Lilly’s unapproved obesity drug, retatrutide, through the FDA’s "compassionate use" program earlier this spring. Amid the resulting speculation, political figures like Senator Maggie Hassan have expressed significant concern, while Representative Ted Lieu publicly questioned whether the President’s recent absences or behaviors might be linked to potential side effects from the drug.

In response to these allegations, White House communications director Steven Cheung dismissed the claims, personally targeting Representative Lieu for spreading rumors. The original report noted that the request for the medication was submitted by a senior NIH clinician to treat a patient suffering from severe obesity, sleep apnea, and pulmonary hypertension. While the administration maintains that the report does not implicate the President, the story has intensified ongoing public curiosity regarding Trump’s health, which has been under scrutiny for months due to reports of hand bruising, swollen ankles, and chronic venous insufficiency.